The Paradigm Shift: Why Quantitative Proteomics is Essential for Multi-Omics
In modern biotechnology, genomics and transcriptomics provide the blueprint and the intermediate templates of life, respectively. However, the ultimate functional execution within biological systems is carried out by proteins. Quantitative proteomics has emerged as a cornerstone of multi-omic solution development, bridging the gap between genetic potential and actual phenotypic expression. By measuring precise protein abundance, post-translational modifications (PTMs), and protein-protein interactions, researchers gain a high-fidelity view of cellular dynamics that sequence-based methods alone cannot capture.
The integration of quantitative proteomics into multi-omic workflows allows for the validation of transcriptomic data, as mRNA expression levels often correlate poorly with protein abundance due to post-transcriptional regulation, translation efficiency, and degradation rates. Consequently, developing comprehensive multi-omic solutions requires a unified approach where proteomic datasets are aligned with genomic, epigenomic, and metabolomic profiles to construct precise molecular maps of health, disease, and agricultural traits.
The Multi-Omic Synergy
Integrating genomics with quantitative proteomics reveals how genomic variations (like SNPs or CNVs) translate into functional changes at the proteome level. This is crucial for identifying targetable disease mechanisms and validating drug responses in clinical trials.
Commercial and Industrial Status of Quantitative Proteomics
The commercial landscape of quantitative proteomics is undergoing rapid expansion. Pharmaceutical and biotechnical corporations are increasingly moving away from single-omic target discovery to multi-omic drug discovery pipelines. Today, quantitative proteomics is heavily integrated into preclinical development, toxicology studies, and biomarker discovery programs. The global market is driven by demand for high-throughput mass spectrometry (MS) services, advanced bioinformatics platforms, and standardized workflows that can scale to accommodate large clinical cohorts.
Industrially, the focus has shifted toward high-throughput automation and reproducibility. Standardized operating procedures (SOPs) and automated sample preparation platforms (such as liquid handling robots) have minimized batch effects, making large-scale quantitative proteomics viable for multi-omic clinical trials. Companies are leveraging Data-Independent Acquisition (DIA) and Tandem Mass Tagging (TMT) multiplexing to analyze thousands of proteomes per week, providing deep coverage of the human plasma, tissue, and cellular proteomes.
Moreover, clinical trial designs now routinely incorporate longitudinal proteomic profiling to monitor patient response to therapies in real time. In the agricultural biotechnology sector, industrial proteomic solutions are deployed to optimize crop resilience, understand host-pathogen interactions, and engineer superior livestock breeds, demonstrating the vast cross-industry utility of these technologies.
Future Development Trends: AI, Single-Cell, and Spatial Resolution
Several key trends are defining the future of quantitative proteomics within the multi-omic ecosystem:
Single-Cell Proteomics
While single-cell RNA sequencing (scRNA-seq) has revolutionized biology, translating these findings to the protein level is critical. Emerging mass spectrometry techniques and ultra-high sensitivity chromatography now enable the quantification of thousands of proteins from a single cell, allowing researchers to explore cellular heterogeneity with unprecedented resolution.
Spatial Proteomics
Understanding where proteins reside within their native tissue microenvironment is essential for understanding disease progression, particularly in oncology and immunology. Combining spatial transcriptomics (such as the BMKMANU S3000 platform) with multiplexed spatial antibody-based profiling represents the next frontier in multi-omic solution development.
AI-Driven Bioinformatics
The sheer volume of data generated by multi-omic experiments requires advanced computational tools. Artificial intelligence and machine learning models are now routinely used to predict peptide properties, automate spectrum identification, and integrate heterogeneous datasets (genomics, transcriptomics, proteomics) to identify predictive biomarkers and therapeutic targets.
These technological advancements ensure that quantitative proteomics is not just an auxiliary tool, but a primary driver of discovery in systems biology, clinical diagnostics, and personalized medicine.
Deep Application Scenarios: Clinical, Agricultural & Environmental Omics
The application of quantitative proteomics within multi-omic frameworks is highly diverse, spanning several critical domains:
1. Clinical Biomarker Discovery and Patient Stratification
In oncology, identifying patients who will respond to specific immunotherapies remains a challenge. By combining whole-genome sequencing (to identify mutational burden) with quantitative proteomics (to identify active signaling pathways and immune checkpoint protein expression), clinicians can build multi-omic models that predict therapeutic efficacy with high precision. Furthermore, longitudinal plasma proteomics allows for the early detection of disease relapse long before clinical symptoms manifest.
2. Agricultural Multi-Omics for Climate Resilience
Climate change demands the rapid development of crops that can withstand drought, salinity, and extreme temperatures. Genomic selection identify promising genetic variants, but quantitative proteomics reveals the active physiological responses—such as the upregulation of heat-shock proteins or osmotic adjustment enzymes. Integrating transcriptomics and proteomics helps researchers pinpoint the exact regulatory networks that control stress tolerance, accelerating breeding programs.
3. Environmental Metaproteomics
In microbiomics, understanding "who is there" (metagenomics) is only half the battle; understanding "what they are doing" (metaproteomics) is crucial. Quantitative metaproteomics measures the functional output of microbial communities in soil, marine environments, or the human gut. This multi-omic approach is vital for soil health assessment, bioremediation projects, and understanding the gut-brain axis.
Biomarker Technologies (BMKGene): Global Multi-Omics Pioneers
Biomarker Technologies (BMKGene), founded in 2009, is a leading genomics service provider with over 16 years of continuous innovation in high-throughput sequencing and bioinformatics. Backed by more than 60 national invention patents and 200+ software copyrights, we deliver comprehensive multi-omics solutions—spanning genomics, metagenomics, epigenetics, single-cell omics, transcriptomics, and our proprietary BMKMANU S3000 spatial transcriptome technology—supported by our advanced BMKCloud bioinformatics platform. We have established long-term collaborations with organizations across 84 regions worldwide, providing reliable genomic solutions on a global scale.
Our Advanced Multi-level High-throughput Platforms
Diverse Sequencing & MS Platforms
PacBio platforms: Sequel II, Sequel, RSII
Nanopore platforms: PromethION P48, GridION X5 MinION
10X Genomics: 10X ChromiumX, 10X Chromium Controller
Illumina platforms: NovaSeq
BGI-sequencing platforms: DNBSEQ-G400, DNBSEQ-T7
Bionano Irys system
Waters XEVO G2-XS QTOF
QTRAP 6500+
State-of-the-Art Laboratory Facility
Over 20,000 square feet facility equipped with advanced biomolecular laboratory instruments.
Standardized laboratories dedicated to sample extraction, library construction, clean rooms, and high-throughput sequencing.
Standard operating procedures (SOPs) strictly enforced from sample extraction to sequencing to ensure maximum data quality and reproducibility.
Reliable, Easy-to-use Bioinformatic Platform
Our self-developed BMKCloud platform empowers researchers with seamless data analysis and visualization capabilities.
Equipped with CPUs featuring 41,104 memory and 3 PB total storage.
Boasts 4,260 computing cores with peak computing power exceeding 121,708.8 Gflop per second, enabling rapid multi-omic data integration.
Fully Automated Platform for Next-generation sequencing--Brilliant Lab 1000
Biomarker technologies (BMKGENE) and PerkinElmer have jointly built a fully automated experimental production line, called Brilliant Lab 1000 (BL1000), which is applied to the high-throughput NGS library construction service.
BMKGENE strives to greatly improve the entire line of sequencing products in terms of product types, production line throughput, delivery quality, and cycle time, to provide customers with better sequencing services.
Enterprise Qualification & Global Standards
BMKGene is committed to maintaining the highest industry standards for quality control, environmental management, and occupational health. Our extensive portfolio of patents and academic collaborations underscores our dedication to scientific excellence.
For inquiries about our products or pricelist, please leave your email to us.
We will be in touch within 24 hours.
Inquiry Now
